Hepatology
Expert perspectives on liver disease, viral hepatitis, cirrhosis management, and liver transplantation.
Recent Discussions
How do you explain the additional risks that a transplant recipient may carry by pursuing a hepatitis C positive organ if they are negative?
I generally counsel that the risks are there from an infection-transmission perspective but that the treatment of hepatitis C is so facile and easily done now that there are not any long term risks. As long as we can get hepatitis C treatment started with the first few months after transplant (in re...
When would you choose to measure a patient's spleen stiffness?
While there is data to support the use of spleen stiffness to assess for clinically significant portal hypertension, spleen stiffness has not yet made the leap to clinical care, at least in my practice. One population where I would consider using it would be in patients with Fontan-associated liver ...
Who would be the right candidate in which TIPS placement would reduce portal hypertension to allow for a previously unattainable procedure?
I would put a TIPS in patients whose only problem is portal hypertension and no significant liver dysfunction, such as cirrhotic patients whose HCV is cured, or abstinent alcoholics, or any other patients whose underlying etiology is controlled.
What role do you see for albumin infusions in patients with hypoalbuminemia to help assist in volume status, outside of its use in replenishment after a large volume paracentesis or renal dysfunction?
I do not give albumin infusions for hyponatremia per se. However, I do give albumin for renal dysfunction and hyponatremia.
How does the use of checkpoint inhibitors for treatment of HCC impact timing of liver transplant and subsequent immunosuppression?
This is a challenging issue with concerns for checkpoint inhibitor/immunotherapy (IO) resulting in rejection of a transplanted organ. In our practice, we have a local protocol based on our consensus that at least 6 weeks of washout for IO prior to transplantation. Post-transplantation, IO is not use...
How do you approach treatment options for patients with fibrolamellar HCC compared to "normal" HCC?
Fibrolamellar HCC is a very rare cancer, reported to account for 1% of all primary liver cancers, and it has distinct differences compared to normal HCC. Patients with fibrolamellar are younger (20s - 30s) than patients with HCC and do not have underlying chronic liver disease, and often present wit...
How does the identification of a hepatic adenoma in a male patient affect your management and evaluation?
Hepatic adenomas (HCA) are benign liver tumors that nonetheless carry risks of hemorrhage and malignant transformation. There are several molecular subtypes of HCA, including: HNF-1α–inactivated HCA Inflammatory HCA β-catenin–activated HCA Unclassified HCA Of these, β-catenin–activated HCA is of p...
How much do you factor in a patient's frailty in selection for transplant if the underlying driver for their debility is their underlying liver disease itself?
It really depends on your LT program's level of comfort with rehabilitating a frail patient post-LT, and whether the patient has shown engagement with physical therapy/rehabilitation prior to transplant. In my opinion, a resilient and well-motivated patient who has shown engagement in some form or r...
What would be the right patient profile and experience for someone who may have (operational) tolerance and how do you approach immunosuppresison management (or withdrawal) in this patient?
We try our very best to minimize immunosuppression (IS) in all patients. A very small subset of patients post-liver transplant (LT) can stop all IS, unlike other solid organ transplants. We don't actively discontinue all IS in patients, but have several patients who have done so on their own, remain...
How do you determine which patients are good candidates to have their organ receive machine perfusion therapy before implantation?
Machine perfusion is being used more and more for DCD grafts resulting in less incidence for ischemic cholangiopathy, thus allowing more DCD organs to be considered and used. Transplant programs are using machine perfusion for more complicated surgical cases such as retransplants and in order to uti...